Loading...
XSTO
IRLABa
Market cap21mUSD
Jun 25, Last price  
3.85SEK
1D
-3.02%
1Q
-44.84%
IPO
-93.45%
Name

IRLAB Therapeutics AB

Chart & Performance

D1W1MN
P/E
—
P/S
2.11
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.66%
Rev. gr., 5y
415.48%
Revenues
95m
+1,566.57%
54,0002,880,000144,000109,00018,00026,000300,000207,782,00061,136,0005,678,00094,628,000
Net income
-83m
L-53.26%
3,122,000-11,887,000-42,696,000-56,225,000-74,099,000-96,318,000-91,848,00051,781,000-114,203,000-177,839,000-83,129,000
CFO
-66m
L-60.21%
-11,024,000-27,655,000-40,818,000-57,741,000-70,790,000-91,201,000-89,214,000128,641,000-142,612,000-164,850,000-65,590,000
Earnings
Jul 08, 2025

Profile

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.
URL
https://irlab.se/
IPO date
Feb 28, 2017
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
94,628
1,566.57%
5,678
-90.71%
61,136
-70.58%
Cost of revenue
279,724
444,453
Unusual Expense (Income)
NOPBT
94,628
(274,046)
(383,317)
NOPBT Margin
100.00%
Operating Taxes
797
Tax Rate
NOPAT
94,628
(274,046)
(384,114)
Net income
(83,129)
-53.26%
(177,839)
55.72%
(114,203)
-320.55%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,771
BB yield
-0.71%
Debt
Debt current
56,885
2,940
3,595
Long-term debt
10,491
27,681
4,357
Deferred revenue
Other long-term liabilities
Net debt
459
(80,688)
(244,824)
Cash flow
Cash from operating activities
(65,590)
(164,850)
(142,612)
CAPEX
(199)
(293)
(3,376)
Cash from investing activities
(199)
(293)
(3,376)
Cash from financing activities
21,396
23,676
(3,134)
FCF
91,507
(272,709)
(383,775)
Balance
Cash
66,917
111,309
252,776
Long term investments
Excess cash
62,186
111,025
249,719
Stockholders' equity
(657,571)
(574,441)
(399,374)
Invested Capital
750,626
717,771
694,181
ROIC
12.89%
ROCE
101.69%
EV
Common stock shares outstanding
51,868
51,868
51,832
Price
10.75
43.33%
7.50
-80.42%
38.30
-12.95%
Market cap
557,585
43.33%
389,013
-80.40%
1,985,162
-12.81%
EV
558,044
308,325
1,740,338
EBITDA
94,628
(269,730)
(379,335)
EV/EBITDA
5.90
Interest
10,477
198
297
Interest/NOPBT
11.07%